NuCana PLC Net Assets
NuCana PLC net assets. Based on the latest financial reports, NuCana PLC (NCNA) has net assets worth $20.14 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.63 Million) and total liabilities ($5.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NuCana PLC (NCNA) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.14 Million |
| % of Total Assets | 78.58% |
| Annual Growth Rate | 81.51% |
| 5-Year Change | -62.89% |
| 10-Year Change | -3.62% |
| Growth Volatility | 24920.01 |
Net Assets of NuCana PLC (2014–2025)
Net assets of NuCana PLC from 2014 to 2025. This chart illustrates how NuCana PLC's net assets have evolved over time, based on quarterly financial data. See NuCana PLC (NCNA) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for NuCana PLC (2014–2025)
The table below shows the annual net assets of NuCana PLC from 2014 to 2025. For live market cap and overall valuation, see market value of NuCana PLC.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $24.33 Million | +308.58% |
| 2024-12-31 | $5.95 Million | -60.01% |
| 2023-12-31 | $14.89 Million | -61.33% |
| 2022-12-31 | $38.50 Million | -41.26% |
| 2021-12-31 | $65.55 Million | -33.94% |
| 2020-12-31 | $99.23 Million | +56.21% |
| 2019-12-31 | $63.52 Million | -22.15% |
| 2018-12-31 | $81.59 Million | -12.66% |
| 2017-12-31 | $93.42 Million | +270.11% |
| 2016-12-31 | $25.24 Million | -15.75% |
| 2015-12-31 | $29.96 Million | +86722.11% |
| 2014-12-31 | $34.51K | -- |
Equity Component Analysis
This analysis shows how different components contribute to NuCana PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25232310774.0% over the analyzed period, potentially due to dividend distributions or operating losses.
NuCana PLC Net Assets Breakdown (December 2025)
NuCana PLC net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $14.34 Million | 58.95% |
| Other Comprehensive Income | $87.08 Million | 357.94% |
| Other Components | $175.25 Million | 720.38% |
| Total Equity | $24.33 Million | 100.00% |
NuCana PLC Competitors by Market Cap
The table below lists competitors of NuCana PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Visible Gold Mines Inc
V:VGD
|
$4.17 Million |
|
Karma Energy Limited
NSE:KARMAENG
|
$4.17 Million |
|
Metal Bank Ltd
AU:MBK
|
$4.17 Million |
|
Ecora Resources PLC
LSE:ECOR
|
$4.17 Million |
|
Forterra PLC
LSE:FORT
|
$4.16 Million |
|
Rare Earth Magnesium Technology Group Holdings Limited
STU:GPS
|
$4.16 Million |
|
Boutique Newcity Public Company Limited
BK:BTNC
|
$4.15 Million |
|
Duksung Co Ltd
KO:004835
|
$4.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NuCana PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,954,000 to 24,327,000, a change of 18,373,000 (308.6%).
- Net loss of 29,353,000 reduced equity.
- New share issuances of 20,185,000 increased equity.
- Other comprehensive income increased equity by 8,654,000.
- Other factors increased equity by 18,887,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-29.35 Million | -120.66% |
| Share Issuances | $20.18 Million | +82.97% |
| Other Comprehensive Income | $8.65 Million | +35.57% |
| Other Changes | $18.89 Million | +77.64% |
| Total Change | $- | 308.58% |
Book Value vs Market Value Analysis
This analysis compares NuCana PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.09x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $5.59 | $1.00 | x |
| 2015-12-31 | $4709.21 | $1.00 | x |
| 2016-12-31 | $3967.46 | $1.00 | x |
| 2017-12-31 | $14918.56 | $1.00 | x |
| 2018-12-31 | $12761.03 | $1.00 | x |
| 2019-12-31 | $9825.52 | $1.00 | x |
| 2020-12-31 | $13097.94 | $1.00 | x |
| 2021-12-31 | $6297.85 | $1.00 | x |
| 2022-12-31 | $3685.46 | $1.00 | x |
| 2023-12-31 | $1415.92 | $1.00 | x |
| 2024-12-31 | $401.27 | $1.00 | x |
| 2025-12-31 | $10.83 | $1.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NuCana PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -120.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.23x
- Recent ROE (-120.66%) is below the historical average (-78.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -17.89% | 0.00% | 0.00x | 1.03x | $-9.62K |
| 2015 | -17.80% | 0.00% | 0.00x | 1.06x | $-8.33 Million |
| 2016 | -23.96% | 0.00% | 0.00x | 1.08x | $-8.57 Million |
| 2017 | -24.71% | -8157.24% | 0.00x | 1.03x | $-32.43 Million |
| 2018 | -16.96% | 0.00% | 0.00x | 1.07x | $-22.00 Million |
| 2019 | -33.71% | 0.00% | 0.00x | 1.11x | $-27.76 Million |
| 2020 | -30.92% | 0.00% | 0.00x | 1.09x | $-40.60 Million |
| 2021 | -61.84% | 0.00% | 0.00x | 1.18x | $-47.09 Million |
| 2022 | -83.17% | 0.00% | 0.00x | 1.51x | $-35.87 Million |
| 2023 | -185.61% | 0.00% | 0.00x | 1.87x | $-29.12 Million |
| 2024 | -319.06% | 0.00% | 0.00x | 2.48x | $-19.59 Million |
| 2025 | -120.66% | 0.00% | 0.00x | 1.23x | $-31.79 Million |
Industry Comparison
This section compares NuCana PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NuCana PLC (NCNA) | $20.14 Million | -17.89% | 0.27x | $4.16 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metab… Read more